Erythrocyte membrane stabilization by indomethacin

Indian Journal of Pharmacology 1993; 25: 173 LETTER TO THE EDITOR
ERYTHROCYTE MEMBRANE STABILIZATION BY INDOMETHACIN
(Accepted for publication: April 06, 1993) The erythrocyte osmotic fragility tests has been used Figure 1. Osmotic fragility profile of erythrocytes. Each point is
as a measure of red cell tensile strength and is the mean of at least four experiments.
related to cellular deformability which is a significantaspect of red cell function.’ Indomethacin, a non- steroidal anti-inflammatory drug, was found to in-duce slight membrane changes in erythrocytes.²We studied the effect of indomethacin on erythrocyte osmotic fragility to ascertain its membrane stabilizing
effect.
Young albino rats (Charles foster) weighing 200- 2509 were maintained on commercial rat diet (Lip- ton Co., India) and water, They were divided intotwo groups. Animals in group I served as control and group II were administered indomethacin 0.4166mg/kg, p.o., bd x 5 days. After 5 days of drug treat- ment blood was collected in heparin (10 IU/ml) from the caudal vein. The osmotic fragility determinations were done by the method of Dacie and Lewis.³ The NaCl concentration of 50% hemolysis was taken as a measure of mean erythrocyte fragility (MEF).
membranes and organelles, any effect of a drug on In control rats, the osmotic fragility (O.F.) profile is the osmotic hemolysis can be interpreted as an almost a sigmoidal curve whereas in indomethacin effect on the cell membrane. The stabilizing effect treated animals the O.F. profile is shifted to the left of indomethacin on erythrocyte membrane may be which is due to decreased osmotic fragility showing membrane stabilization (Figure 1). The MEF is sig- shown to cause phospholipids disruption, an impor- nificantly (P < 0.01) decreased in indomethacin tant component of red cell membranes and as- treated rats. The MEF of control and indomethacin sociated structural changes in the red cell membrane treated rats are 0.740 ± 0.008 and 0.711 ± 0.002% lndomethacin is one of the most potent inhibitorsof the prostaglandin forming cyclooxygenase which IMTIAZ AHMAD* AND MOHAMMAD SUHAI L
reduces the production and tissue concentration of to act on erythrocytes in such a way that it causes * Present Address: Institute of Social Health Welfare Rural been reported that ingestion of indomethacin in- Development and Educational Society, ISWRDES (India), duces slight membrane changes in erythrocytes.² Since erythrocytes are free from intracellular REFERENCES
U.S. Department of the Army TM8-227-4. Laboratory proce- dures in clinical hematology. Washington D.C., U.S. Govt.
4. Goodman LS, Gilman A. The pharmacological basis of therapeutics. 7th eds. New York: McMillan Publishing Co.
Mazorow DL, Hang A, Bull R, McGroarty EJ. Effect of aspirin, indomethacin and sodium salicylate on human erythrocytemembranes as detected with electron spin resonance 5. Taniguchi M, Alkawa M, Sakagami T Effect of prostaglandin spectroscopy. Throm Res 1985;40:779-92.
and polyphloretin phosphate on hemolysis of human eryrhrocytes. J Biochem 1982;91:1173-9.
Dacie JV, Lewis S.M. Practical hematology. Orient

Source: http://www.aimsm.com/research_papers/Erythrocyte%20membrane%20stabilization%20by%20Indomethacin.1993--2.pdf

Chapter 5

Engaging Citizens In Natural Resource Decisions, Part 2 Abstract  This two-part article explores the lessons we have learned from our work helping citizens and decision makers engage in collaborative governance on land use, natural resource, and environmental issues. Part I described a range of natural resource problems and examined what makes some intractable, or ‘wicked’ and proposed a

Sa_jan06_ppkim_smith.indd

technical post-balance sheet eventsrelevant to Professional Scheme Paper 3.1 Candidates attempting Paper 3.1 should CASE STUDY following issues arising during the final audit find Question 3 relatively straightforward, as By way of a case study, consider Question 3 of have been noted on a schedule of points for its style and standard have barely changed the June 2005 exam. Th

Copyright © 2008-2018 All About Drugs